DiaSorin SpA received Emergency Use Authorization from the U.S. Food and Drug Administration for a new serologic test for Covid-19.

The Liaison test is one of the first based on so-called Chemiluminescent ImmunoAssay technology to receive such authorization in the U.S., DiaSorin said Saturday in a statement. The Italian company is boosting output capacity at its Saluggia site to make several million Liaison tests in the coming months.

Earlier in April, DiaSorin said it had “CE-marked” the test, known formally as Liaison Sars-Cov-2 S1/S2 IgG, and was submitting the product to the FDA for authorization.